



NDA 021366/S-043  
NDA 021366/S-044

## SUPPLEMENT APPROVAL

AstraZeneca Pharmaceuticals LP  
Agent for iPR Pharmaceuticals, Inc.  
Attention: Sally Walsh  
Regulatory Affairs Director  
One MedImmune Way  
Gaithersburg, MD 20878

Dear Ms. Walsh:

Please refer to your supplemental new drug applications (sNDAs) and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Crestor (rosuvastatin calcium) tablets.

### **Supplement 043**

This Prior Approval sNDA, dated and received May 20, 2021, provides for changes to the Prescribing Information and Patient Package Insert for Crestor according to the FDA Prior Approval Supplement Request Letter dated March 23, 2021, for the following updates:

- Revised Section 4 – *Contraindications* to remove contraindications for use during Pregnancy and Lactation
- Revised Section 5.2 - *Warnings and Precautions* Section on Immune-Mediated Necrotizing Myopathy to remove “Consider risk of IMNM carefully prior to initiation of a different statin. If therapy is initiated with a different statin, monitor for signs and symptoms of IMNM.” and add “There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered.”
- Added lichenoid drug eruption to Section 6.2 *Postmarketing Experience*
- Revised Section 8 – *Use in Special Populations*
- Revised Section 13 – *Nonclinical Toxicology*
- Revised Section 17 – *Patient Counseling Information*
- Extensive edits made throughout the Prescribing Information and Patient Package Insert to update and modernize.

### **Supplement 044**

This Prior Approval sNDA, dated and received February 10, 2022, provides for updates to the Crestor Prescribing Information Section 6.2 *Post-marketing Experience* with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and updates Section 12.3 *Pharmacokinetics* with the drug-drug interactions (DDIs) involving rosuvastatin with the concomitant use of fostamatinib, capmatinib, febuxostat, and teriflunomide.

### **APPROVAL & LABELING**

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [FDA.gov](http://FDA.gov).<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 021366/S-043

NDA 021366/S-044

Page 4

If you have any questions, contact Martin White, MS, Regulatory Project Manager, at 240-402-6018.

Sincerely,

*{See appended electronic signature page}*

John Sharretts, M.D.  
Director  
Division of Diabetes, Lipid Disorders, and Obesity  
Office of Cardiology, Hematology,  
Endocrinology, and Nephrology  
Office of New Drugs  
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

JOHN M SHARRETTS  
01/13/2023 02:42:40 PM